Journal
CARDIOVASCULAR DRUG REVIEWS
Volume 25, Issue 2, Pages 162-174Publisher
WILEY
DOI: 10.1111/j.1527-3466.2007.00012.x
Keywords
angiotensin-(1-7); cancer; cardiac arrhythmias; cardiac hypertrophy; heart failure; hypertension
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051952] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL-51952] Funding Source: Medline
Ask authors/readers for more resources
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available